Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)
← catalyst calendarNCT07730528 · readout ≤ 1,503 d
Sponsored by Humacyte, Inc. (industry) · HUMA — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Sep 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Coronary Artery Disease
Intervention
- Biological: Humacyte Coronary Tissue Engineered Vessel (CTEV)
Primary outcome
what the primary-completion date above is the date OFRate of events (MACE, AE, AESI, etc.) in all participants implanted with CTEV
measured 36 months
Permalink · HUMA's whole pipeline · Catalyst calendar · Every registered study · What changed